KCT0001784已完成未知
A study to assess the pharmacokinetic characteristics of sumatriptan after oral administration in healthy adult volunteers
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 12
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional Study
入排标准
- 年龄范围
- 19(Year) 至 o Limit（—）
- 性别
- All
入选标准
- •1) Healthy male subject aged =19 years at screening
- •2) Body weight of = 50 kg and within ± 20% of ideal body weight
- •? IBW (kg) = height (cm) - 100} * 0.9
- •3) Subject that is considered eligible for medical history and physical examination conducted in accordance with the study protocol, with no congenital or chronic disease
- •4) Subject that is considered eligible for participating in the study by an investigator, based on clinical laboratory test (serology, hematology, clinical chemistry, urinalysis, etc.) and ECG, prior to administration of study drug (results : normal or no clinical significant)
- •5) wonen who are not pregnant
- •6) Subjects who understand a detailed explanation of the study protocol, voluntarily decide to participate and follow the study instructions, and sign Informed Consent
排除标准
- •1) Medical History of clinically significant hypersensitivity to study drug (major ingredient or any other ingredient)
- •2) congenital or chronic disease, pathological symptoms or findings of medical examination
- •3) History of gastrointestinal disease (e.g., Crohn’s disease, active peptic ulcer) or gastrointestinal surgery that may affect the absorption of the study drug (excluding simple appendectomy or herniorrhaphy)
- •4) History of major injury, surgical operation, or suspected symptom of acute illness within 4 weeks prior to the first administration of study drug
- •5) history of drug abuse
- •6) Use of any prescribed drugs or herbal remedies within 2 weeks, or use of any over-the-counter medication within 1 week prior to the first administration of study drug, and this will affect this study or the safety of the subjects in the opinion of the investigator
- •7) Participation in any other study within 3 months prior to the first administration of study drug (The completion date of previous study is the day of the last administration of study drug)
- •8) Donation of whole blood within 2 months prior to the first administration of study drug, or donation of any blood component within 1 month prior to the first administration of study drug
- •9) History of excessive alcohol abuse (>21 units/week, 1 unit=10g=12.5mL of pure alcohol), or subjects who cannot abstain from drinking during the study period
- •10) excessive smoking (>20 cigarettes/day)
- •11) Abnormal diet that may affect absorption, distribution, metabolism and excretion of drugs (*e.g., Grapefruit juice = 1L /day within 7 days prior to administration of study drug)
- •12) Subject that is not eligible to participate at the discretion of study investigator
研究者
相似试验
已完成
1 期
A study to define the pharmacokinetic properties of lignocaine gel applied topically on a surgical fieldACTRN12611001201965Medortus Inc12
已完成
不适用
A clinical study to evaluate the pharmacokinetics of colistin and to explore biomarkers for nephrotoxicity in healthy volunteersKCT0005944Kyung Hee University Hospital12
进行中（未招募）
不适用
A study in Rheumatoid Arthritis patients to look at two formulations of adalimumab for pharmacokinetics and safety.MedDRA version: 14.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid ArthritisEUCTR2012-000535-36-CZAbbott GmbH & Co. KG100
进行中（未招募）
不适用
A study in Rheumatoid Arthritis patients to look at two formulations of adalimumab for pharmacokinetics and safety.MedDRA version: 14.1Level: PTClassification code 10039073Term: Rheumatoid arthritisSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersRheumatoid ArthritisEUCTR2012-000535-36-DEAbbVie Deutschland GmbH & Co. KG100
进行中（未招募）
不适用
A study in Rheumatoid Arthritis patients to look at two formulations of adalimumab for pharmacokinetics and safety.Rheumatoid ArthritisEUCTR2012-000535-36-PLAbbott GmbH & Co. KG100